President Donald Trump will deliver his first major speech on drug prices on April 26; a recent Medicare Payment Advisory Commission proposal would cut Medicare payment rates by 30% for some services at hospital-affiliated free-standing emergency departments; nursing homes routinely turn away patients seeking care if they are using medication-assisted treatment to treat substance use disorder for opioids.
President Donald Trump will deliver his first major speech about drug prices on April 26, Politico reported. Based on his fiscal 2019 budget request, he could advocate for Medicare and Medicaid demonstrations to test new ways of paying for drugs on a smaller scale, like allowing some states to try negotiating drug costs in Medicaid. He is unlikely to call for the sort of actions he did when he was a candidate, like allowing the government to negotiate the cost of drugs for Medicare.
A recent Medicare Payment Advisory Commission (MedPAC) proposal would cut Medicare payment rates by 30% for some services at hospital-affiliated free-standing emergency departments (EDs) that are located within 6 miles of an on-campus hospital ED, Kaiser Health News reported. Free-standing EDs have been growing and now number more than 500. The proposal is spurred by concerns that MedPAC’s payment for services at these facilities is higher than it should be since the patients who visit them are sometimes not as severely injured or ill as those at hospital facilities.
Nursing homes routinely turn away patients seeking care if they are using medication-assisted treatment (MAT) to treat substance use disorder for opioids—a practice that legal experts say violates the Americans with Disabilities Act, STAT reported. After hospital discharge, many patients require further nursing care. But STAT has found that many nursing facilities refuse to accept such patients, often because of stigma, gaps in training, and the widespread misconception that abstinence is superior to medications for treating addiction. Nursing home staff may be unfamiliarity with MAT. Facilities may not have a clinician on staff licensed to prescribe buprenorphine and may be unaware that the patient’s primary care doctor often can continue to provide the medicine.
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More